ClinicalTrials.gg
Active, not recruitingNCT03893955Updated Sep 2, 2026

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of ABBV-927 and ABBV-368 in Cancer, Advanced Solid Tumors and Triple-Negative Breast Cancer (TNBC), sponsored by AbbVie. Active, not recruiting at 26 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors. This study consists of 2 main parts, a dose-escalation phase and a dose-expansion phase. The dose-expansion phase can begin once the recommended phase 2 dose/maximum tolerated dose (RP2D/MTD) is determined in the dose-escalation phase.

02

Conditions studied

  • Cancer
  • Advanced Solid Tumors
  • Triple-Negative Breast Cancer (TNBC)
  • Non-small-cell-lung-cancer (NSCLC)
  • Metastatic Solid Tumors

Keywords

  • Cancer
  • Advanced Solid Tumors
  • Triple-Negative Breast Cancer (TNBC)
  • Non-small-cell-lung-cancer (NSCLC)
  • ABBV-927
  • ABBV-368
  • ABBV-181
  • metastatic solid tumors
  • dose-escalation
  • recommended phase 2 dose
  • budigalimab
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 150 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.

Of its 360 completed or terminated interventional studies of FDA-regulated products, 216 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adequate liver, kidney and hematology function as demonstrated by laboratory values detailed in the study protocol.
  • An (ECOG) performance status of 0 or 1.

Dose-Escalation:

  • Arm A: Participants with an advanced solid tumor who have progressed on standard therapies known to provide clinical benefit and/or participants who have refused or are intolerant of such therapy.
  • Arm B (non-small-cell-lung-cancer [NSCLC]): Participants with or cytologically confirmed NSCLC who previously progressed during or after an anti-programmed cell death (PD)-1 or PD ligand 1 () therapy and a platinum-based regimen in the recurrent or setting.

Dose-Expansion:

  • Arm 1, 2, and 3 (triple-negative breast cancer [TNBC]): Participants with histologically or cytologically confirmed breast adenocarcinoma that is estrogen receptor/progesterone receptor/human epidermal growth factor receptor (HER)2-negative who must have disease progression during or after at least 1 systemic therapy that included a taxane in the metastatic or recurrent setting and who are treatment-naïve to immunotherapy.
  • Arm 4 (TNBC): Participants with histologically or cytologically confirmed TNBC who have received no previous anti-cancer therapy for TNBC, and who are PD-L1 negative on tumor tissue by immunohistochemistry (IHC) assay.
  • Arm 5 (NSCLC): Participants with histologically or cytologically confirmed NSCLC who previously progressed either during or after an anti-PD-1 or PD-L1 therapy and a platinum-based regimen in the recurrent or metastatic setting.

Exclusion criteria

Exclusion Criteria:

  • Has history of inflammatory bowel disease or pneumonitis.
  • Has uncontrolled to the central nervous system.
  • Has a concurrent that is , treatment is required, or the participant is not clinically stable.
  • Has had a major surgery ≤ 28 days prior to the first dose of study drug or the surgical wound is not fully healed.
  • Has previously treated with an anti-PD- or -targeting agent and had during the course of their therapy:
  • any immune-mediated toxicity of Grade 3 or worse severity
  • treatment of the toxicity with systemic
  • any to the PD-1 or PD-L1-targeting agent
  • any treatment-related toxicity resulting in discontinuation of the PD-1 or PD-L1 targeting agent
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Dose Escalation Arm A: ABBV-927 + ABBV-368 Solid Tumors

    Participants with Solid Tumors will receive various doses of ABBV-927 by intravenous (IV) infusion plus ABBV-368. This will determine the recommended phase two dose (RP2D) of ABBV-927.

    Drug: ABBV-927 · Drug: ABBV-368

  • Experimental
    Dose Escalation Arm B: ABBV-927 + ABBV-368 + ABBV-181 NSCLC

    Participants with non-small-cell-lung-cancer (NSCLC) will receive ABBV-927 IV at various dose levels + ABBV-368 + ABBV-181. This will determine the recommended phase two dose (RP2D) of ABBV-927 + ABBV-368 + ABBV-181.

    Drug: ABBV-927 · Drug: ABBV-368 · Drug: ABBV-181

  • Experimental
    Dose Expansion Arm 1: ABBV-927 + Carboplatin + ABBV-368 TNBC

    Participants with Triple Negative Breast Cancer (TNBC) will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin + ABBV-368 by IV.

    Drug: ABBV-927 · Drug: ABBV-368 · Drug: Carboplatin

  • Experimental
    Dose Expansion Arm 2: ABBV-927 + Carboplatin + ABBV-181 TNBC

    Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin + ABBV-181 by IV.

    Drug: ABBV-927 · Drug: ABBV-181 · Drug: Carboplatin

  • Experimental
    Dose Expansion Arm 3: ABBV-927 + Carboplatin TNBC

    Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin by IV.

    Drug: ABBV-927 · Drug: Carboplatin

  • Experimental
    Dose Expansion Arm 4: ABBV-927+ Nab-paclitaxel + ABBV-368 TNBC

    Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Nab-paclitaxel + ABBV-368 by IV.

    Drug: ABBV-927 · Drug: ABBV-368 · Drug: Nab-paclitaxel

  • Experimental
    Dose Expansion Arm 5: ABBV-927 + ABBV-368 + ABBV-181 NSCLC

    Participants with NSCLC will receive ABBV-927 (at the RP2D established in Arm B) + ABBV-368 + ABBV-181 by IV.

    Drug: ABBV-927 · Drug: ABBV-368 · Drug: ABBV-181

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Expansion: Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with either complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: Up to approximately 2 years following the first dose of study drug

  2. Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of ABBV-927 + ABBV-368

    The RP2D of ABBV-927 + ABBV-368 will be determined during the dose-escalation phase of the study. RP2D will be determined using available safety and pharmacokinetics data.

    Time frame: Up to approximately 6 months

  3. Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of ABBV-927 + ABBV-368 + ABBV-181

    The RP2D of ABBV-927 + ABBV-368 + ABBV-181 will be determined during the dose-escalation phase of the study. RP2D will be determined using available safety and pharmacokinetics data.

    Time frame: Up to approximately 6 months

Secondary outcomes

  1. Dose-Expansion Phase: Progression-free Survival (PFS)

    PFS is defined as the time from date of first study drug exposure to disease progression or death, whichever occurs first.

    Time frame: Up to approximately 2 years since the first dose of study drug

  2. Dose-Expansion Phase: Duration of Response (DOR)

    DOR defined as the time from the participant's initial response to study drug therapy to disease progression or death, whichever occurs first.

    Time frame: Up to approximately 2 years since the first dose of study drug

  3. Maximum Serum Concentration (Cmax)

    Maximum Serum Concentration (Cmax)

    Time frame: Up to approximately 12 weeks after participant's initial dose of study drug

  4. Time to Maximum Observed Serum Concentration (Tmax)

    Time to Maximum Observed Serum Concentration (Tmax)

    Time frame: Up to approximately 12 weeks after participant's initial dose of study drug

  5. Area Under the Serum Concentration Versus Time Curve from Time 0 to the Time of the Last Measurable Concentration (AUCτ)

    Area under the serum concentration versus time curve from time 0 to the time of the last measurable concentration (AUCτ).

    Time frame: Up to approximately 12 weeks after participant's initial dose of study drug

  6. Terminal Phase Elimination Half-life (t1/2)

    Terminal Phase Elimination Half-life (t1/2)

    Time frame: Up to approximately 4 weeks after participant's initial dose of study drug

07

Study locations

26 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2019 (actual). Primary completion is estimated for Mar 2027, 94 months after the start.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's planned 94 months is above that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2019
First posted
Mar 28, 2019
StartActual
May 21, 2019
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03893955
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 28, 2019
Start date
May 21, 2019
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Sep 2, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Revdofilimab · Budigalimab

Start the discussion